CEL-SCI Corporation Reports Second Quarter 2008 Financi...( VIENNA Va. May 16 /- CEL-SCI CORP...),Health

VIENNA, Va., May 16 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) reports financial results for the three and six months ended March 31, 2008.

Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We are completely focused on getting our cancer therapy Multikine(R) into its pivotal Phase III clinical trial. We were unable to start the Phase III study until the completion of our dedicated manufacturing facility for Multikine from which we can supply the Phase III study and subsequent sale of the drug. This facility is expected to be completed in the 3rd quarter of 2008. The Phase III study is designed to replicate the safety and efficacy results seen in the earlier studies and lead to an approval to sell Multikine."

Mr. Kersten continued, "Our financial results reflect our primary focus on the facility and preparation for the Phase III trial. Our Phase III trial is the first Phase III trial to test the theory that immune stimulation before surgery, radiation and/or chemotherapy will increase survival of cancer patients."

About Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, MD. Upon completion of the facility in the 3rd quarter of 2008, CEL-SCI will commence the Phase III clinical tr
'/>"/>